OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
HALE.PSX59

Haleon Pakistan Ltd

PharmaceuticalsVerified

Haleon Pakistan Ltd maintains a strong liquidity position, with a current ratio of 1.36, indicating the company can cover its short-term liabilities with its short-term assets. The company's liquidity_fpt score suggests a medium liquidity risk, which is consistent with its operating cash flow of PKR 3.25 billion and free cash flow of PKR 1.04 billion. However, the company's net cash position is negative after subtracting total debt, which may pose a liquidity challenge in the near term. In terms of profitability, Haleon Pakistan Ltd demonstrates a return on equity (ROE) of 12.36% and a return on assets (ROA) of 5.54%. These figures suggest the company is generating reasonable returns for its shareholders and effectively utilizing its assets. The company's operating income of PKR 2.09 billion and net income of PKR 1.22 billion further support its profitability. The debt-to-equity ratio of 0.02 indicates a conservative capital structure with minimal leverage. Geographically, Haleon Pakistan Ltd is primarily focused on the domestic market, with no disclosed international revenue segments. The company's revenue concentration in Pakistan may expose it to local economic and regulatory risks. The company's business is not segmented by product lines in the provided data, but its primary activity is in pharmaceuticals and medical research. Looking at the growth trajectory, the company's revenue for the latest period was PKR 9.81 billion. While the outlook for the current and next fiscal years is not explicitly provided, the company's capital expenditure of PKR -1.09 billion suggests a focus on cost management rather than expansion. The company's free cash flow of PKR 1.04 billion indicates it has the financial flexibility to support operations and potentially fund future growth initiatives. The risk assessment for Haleon Pakistan Ltd highlights a medium liquidity risk and a low dilution risk. The company's dilution potential is low, with no significant changes in shares outstanding between basic and diluted shares. The company's conservative capital structure and strong cash flow position it to manage its debt obligations effectively. However, the negative net cash position after subtracting total debt is a concern that may require monitoring. Recent events and filings for Haleon Pakistan Ltd do not include specific details in the provided data. Analyst estimates suggest a mean price target of PKR 1,134.00, with a median price target of PKR 1,134.00 and a recommendation mean of 2.50, indicating a neutral outlook. The company has one buy and one hold recommendation, with no strong buy recommendations.

30-day price · HLN-0.60 (-6.3%)
Low$8.65High$9.61Close$8.89As of8 Jun, 00:00 UTC
Profile
CompanyHaleon Pakistan Ltd
TickerHALE.PSX
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Haleon Pakistan Ltd operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of healthcare products.

Classification. The company is classified under the Healthcare economic sector and the Pharmaceuticals & Medical Research business sector with a confidence level of 0.92.

Haleon Pakistan Ltd maintains a strong liquidity position, with a current ratio of 1.36, indicating the company can cover its short-term liabilities with its short-term assets. The company's liquidity_fpt score suggests a medium liquidity risk, which is consistent with its operating cash flow of PKR 3.25 billion and free cash flow of PKR 1.04 billion. However, the company's net cash position is negative after subtracting total debt, which may pose a liquidity challenge in the near term. In terms of profitability, Haleon Pakistan Ltd demonstrates a return on equity (ROE) of 12.36% and a return on assets (ROA) of 5.54%. These figures suggest the company is generating reasonable returns for its shareholders and effectively utilizing its assets. The company's operating income of PKR 2.09 billion and net income of PKR 1.22 billion further support its profitability. The debt-to-equity ratio of 0.02 indicates a conservative capital structure with minimal leverage. Geographically, Haleon Pakistan Ltd is primarily focused on the domestic market, with no disclosed international revenue segments. The company's revenue concentration in Pakistan may expose it to local economic and regulatory risks. The company's business is not segmented by product lines in the provided data, but its primary activity is in pharmaceuticals and medical research. Looking at the growth trajectory, the company's revenue for the latest period was PKR 9.81 billion. While the outlook for the current and next fiscal years is not explicitly provided, the company's capital expenditure of PKR -1.09 billion suggests a focus on cost management rather than expansion. The company's free cash flow of PKR 1.04 billion indicates it has the financial flexibility to support operations and potentially fund future growth initiatives. The risk assessment for Haleon Pakistan Ltd highlights a medium liquidity risk and a low dilution risk. The company's dilution potential is low, with no significant changes in shares outstanding between basic and diluted shares. The company's conservative capital structure and strong cash flow position it to manage its debt obligations effectively. However, the negative net cash position after subtracting total debt is a concern that may require monitoring. Recent events and filings for Haleon Pakistan Ltd do not include specific details in the provided data. Analyst estimates suggest a mean price target of PKR 1,134.00, with a median price target of PKR 1,134.00 and a recommendation mean of 2.50, indicating a neutral outlook. The company has one buy and one hold recommendation, with no strong buy recommendations.
Key takeaways
  • Haleon Pakistan Ltd has a strong liquidity position with a current ratio of 1.36 and positive operating and free cash flows.
  • The company's ROE of 12.36% and ROA of 5.54% indicate solid profitability and efficient asset utilization.
  • The company's revenue is concentrated in Pakistan, which may expose it to local economic and regulatory risks.
  • The company's capital expenditure is negative, suggesting a focus on cost management rather than expansion.
  • The company has a low dilution risk, with no significant changes in shares outstanding.
  • Analysts have a neutral outlook on the company, with a mean price target of PKR 1,134.00.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyPKR
Revenue$9.81B
Gross profit$3.30B
Operating income$2.09B
Net income$1.22B
R&D
SG&A
D&A
SBC
Operating cash flow$3.25B
CapEx-$1.09B
Free cash flow$1.04B
Total assets$22.08B
Total liabilities$12.18B
Total equity$9.90B
Cash & equivalents
Long-term debt$235.3M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$24.16B$3.03B$2.13B$1.81B
FY-3$27.51B$1.30B$325.4M-$241.2M
FY-2$31.61B$2.08B$995.6M-$361.0M
FY-1$37.21B$7.71B$4.58B-$157.6M
FY0$43.11B$10.68B$6.37B$1.48B
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$13.87B$6.72B
FY-3$15.06B$7.04B
FY-2$18.24B$8.02B
FY-1$21.80B$11.99B
FY0$27.16B$14.80B
PeriodOCFCapExFCFSBC
FY-4$1.59B-$543.3M$1.81B
FY-3$974.3M-$503.4M-$241.2M
FY-2$2.08B-$1.79B-$361.0M
FY-1$6.64B-$3.19B-$157.6M
FY0$5.58B-$2.01B$1.48B
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$9.81B$2.09B$1.22B$1.04B
FQ-6$9.75B$2.34B$1.33B$910.8M
FQ-5$9.69B$2.16B$1.38B-$2.11B
FQ-4$10.03B$2.17B$1.35B$1.20B
FQ-3$11.60B$2.78B$1.62B-$159.1M
FQ-2$10.56B$2.66B$1.62B$222.7M
FQ-1$10.92B$3.07B$1.79B$220.6M
FQ0$9.59B$2.41B$1.52B$1.28B
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$22.08B$9.90B
FQ-6$23.95B$11.23B
FQ-5$21.80B$11.99B
FQ-4$24.82B$11.58B
FQ-3$25.36B$13.20B
FQ-2$25.17B$13.65B
FQ-1$27.16B$14.80B
FQ0$29.93B$14.57B
PeriodOCFCapExFCFSBC
FQ-7$3.25B-$1.09B$1.04B
FQ-6$4.61B-$1.65B$910.8M
FQ-5$6.64B-$3.19B-$2.11B
FQ-4$1.63B-$74.9M$1.20B
FQ-3$2.29B-$468.0M-$159.1M
FQ-2$2.49B-$859.9M$222.7M
FQ-1$5.58B-$2.01B$220.6M
FQ0$190.7M-$405.7M$1.28B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$9.90B
Net cash-$235.3M
Current ratio1.4
Debt/Equity0.0
ROA5.5%
ROE12.4%
Cash conversion2.7%
CapEx/Revenue-11.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
MetricHALE.PSXActivity
Op margin21.3%2.4% medp25 -91.8% · p75 12.5%top quartile
Net margin12.5%1.2% medp25 -98.4% · p75 10.4%top quartile
Gross margin33.7%45.6% medp25 29.8% · p75 66.7%below median
CapEx / revenue-11.1%-5.2% medp25 -15.8% · p75 -1.7%below median
Debt / equity2.0%9.3% medp25 0.1% · p75 43.8%below median
Observations
IR observations
Mean price target1,134.00 PKR
Median price target1,134.00 PKR
High price target1,318.00 PKR
Low price target950.00 PKR
Mean recommendation2.50 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count1.00
Hold count1.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate63.30 PKR
Last actual EPS54.45 PKR
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-07 02:39 UTC#10b869c4
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 02:27 UTCJob: cf807c52